Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(60.0%)
Phase 3
2(40.0%)
5Total
N/A(3)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04912570Not ApplicableSuspended

Thrombus Aspiration in Heavy Thrombus Burden Acute ST-elevation Myocardial Infarction

Role: lead

NCT05594342Phase 3Unknown

Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support

Role: lead

NCT04738344Not ApplicableWithdrawn

Very Long Versus Overlapping Stents in Long Coronary Lesions

Role: lead

NCT03893435Not ApplicableCompleted

The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction

Role: lead

NCT03926780Phase 3Completed

Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi

Role: lead

NCT03830814Completed

The Effects of Sacubitril/Valsartan on the Heart Functions

Role: lead

All 6 trials loaded